transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia

Författare och institution:
Anna Martner (Sahlgrenska Cancer Center); Anna Rydström (Sahlgrenska Cancer Center); Rebecca E Riise (Sahlgrenska Cancer Center); Johan Aurelius (Sahlgrenska Cancer Center & Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition); H. Anderson (-); Mats Brune (Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition); R. Foa (-); Kristoffer Hellstrand (Sahlgrenska Cancer Center); Fredrik B Thorén (Sahlgrenska Cancer Center)
Publicerad i:
Oncoimmunology, 5 ( 1 ) s. article no. e1041701
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3 /16 /56(bright)) and CD16(+) (CD3 /16(+)/56(+)) natural killer (NK) cells in the blood along with increased NK cell expression of the natural cytotoxicity receptors (NCRs) NKp30 and NKp46. Multivariate analyses correcting for age and risk group demonstrated that high CD56(bright) NK cell counts and high expression of NKp30 or NKp46 on CD16(+) NK cells independently predicted leukemia-free survival (LFS) and overall survival (OS). Our results suggest that the dynamics of NK cell subsets and their NCR expression may determine the efficiency of relapse-preventive immunotherapy in AML.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper ->
Immunologi inom det medicinska området
acute myeloid leukemia, immunotherapy, natural cytotoxicity receptors, natural killer cells, 1st complete remission, acute myelogenous leukemia, nk cells, histamine, dihydrochloride, recombinant interleukin-2, cytokine production, phase-3, trial, transplantation, maintenance, induction, Oncology, Immunology
Postens nummer:
Posten skapad:
2016-05-04 12:05
Posten ändrad:
2016-05-04 12:05

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007